Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.

Sara A HurvitzMiguel MartinMichael F PressDavid ChanMaría Fernandez-AbadEdgar PetruRegan RostorferValentina GuarneriChiun-Sheng HuangSusana BarrigaSameera WijayawardanaManisha BrahmacharyPhilip J EbertAnwar HossainJiangang LiuAdam AbelAmit AggarwalValerie M JansenDennis J Slamon

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Abemaciclib plus anastrozole demonstrated biological and clinical activity with generally manageable toxicities in patients with HR+/HER2- early breast cancer. Abemaciclib led to potent cell-cycle arrest, and in combination with anastrozole, enhanced immune activation.

Keyphrases

cell cycle
phase ii
cell cycle arrest
cell proliferation
early breast cancer
immune response
clinical trial
pi k akt
cell death
open label
rectal cancer
lymph node
locally advanced
anti inflammatory
signaling pathway
dendritic cells
squamous cell carcinoma
placebo controlled